Objectives: Oral corticosteroid treatment is the standard therapy for autoimmune pancreatitis (AIP) and is highly effective. However, relapse may occur during maintenance therapy (MT). We aimed to clarify the predictive factors for relapse after 3 years of MT for use in deciding on the continuation of long-term MT.
A utoimmune pancreatitis (AIP) was established based on a pathological background of lymphoplasmacytic sclerosing pancreatitis, 1 high serum IgG4 concentration, 2 and abundant IgG4-bearing plasma cell infiltration. 3 The characteristic clinical features of AIP, such as elderly male preponderance, obstructive jaundice, and mass-forming lesions in the pancreas, often mimic those of pancreatic cancer. 4 Oral corticosteroid treatment is the standard therapy for AIP and is considered highly effective. 5, 6 The indications for corticosteroids include obstructive jaundice due to a pancreatic head mass lesion, persistent abdominal or back pain, and symptoms due to extrapancreatic vital organ lesions. [7] [8] [9] In the Japanese Consensus Guidelines for Management of AIP 2013, it is recommended that corticosteroids be administered at an initial dose of 0.6 mg/kg/day for 2 to 4 weeks as remission induction therapy and then tapered to a maintenance dose of 5 to 7.5 mg/day over a period of 3 to 6 months. 10 However, relapse may still occur after remission induction; relapse rates are reported to be 40% to 60% after corticosteroid cessation and 20% to 30% during maintenance therapy (MT). 9, [11] [12] [13] Recurrent relapses have been identified as a major risk factor for pancreatic stone formation in AIP, 6, 14, 15 which seems to be closely associated with pancreatic insufficiency due to transition to chronic pancreatitis. 16 Maintenance corticosteroid therapy may prevent relapse and is recommended for a period of at least 3 years, 17 although relapse can occur afterward. Thus, it is preferable to continue MT for longer than 3 years in some cases despite the possible adverse effects of long-term corticosteroid use. 18 There is therefore, debate on whether MT should be extended past 3 years or not. Many reports on AIP have been published to date, but it is difficult to gain objective evidence on AIP relapse risk because of discrepancies in study design, such as patients continuing MT, those without remission induction or MT, and those with interruption of MT. Moreover, many investigations mainly dealt with relapse at the time of initial treatment, with few focusing on relapse during the long-term course after 3 years of MT. The present study investigated relapse after 3 years of MT and aimed to clarify its predictive factors for use in deciding on whether to continue long-term MT.
MATERIALS AND METHODS
We recruited 56 patients with type 1 AIP who were treated at our clinic or affiliated hospitals for at least 5 years from the time of diagnosis by December 31, 2015. Autoimmune pancreatitis was diagnosed based on the International Consensus Diagnostic Criteria for AIP 2011 or the Japanese Diagnostic Criteria for AIP 2011. 19, 20 Ultimately, 38 patients (male ratio, 82%; median age at AIP diagnosis, 62 years) were selected for further study, with 18 patients being excluded based on the exclusion criteria of a nondefinite AIP diagnosis for 5 patients, no corticosteroid therapy for 5 patients, insufficient clinical records of long-term follow-up at another hospital for 1 patient, and discontinued corticosteroid therapy for 7 patients, among whom 2 patients had severe adverse effects (fracture and femur head necrosis) and 5 patients attempted corticosteroid cessation. All patients received prophylactic treatment of pathological fracture, gastric ulcer, and pneumocystis carini infection. These 38 AIP patients were administered corticosteroids as remission induction therapy, which were tapered to a maintenance dose for 3 to 6 months based on the Japanese Consensus Guidelines for Management of AIP 2013, 10 and continued MT for the standard 3 years and then an additional 2 years. These periods included remission induction therapy term and dose-up term for relapse. None of the 38 patients attempted corticosteroid discontinuation during the clinical course.
Median follow-up period was 10.9 years (range, 5.2-23.4 years). The subjects were divided into 2 groups for analysis: the relapse group for patients who experienced relapse after 3 years of MT and the nonrelapse group for those who did not. Relapse during the 3 years immediately after corticosteroid introduction was ignored in this group selection.
Previous reports have adopted different definitions for AIP relapse, including reappearance of symptoms after remission induction therapy or after interruption of MT, 21 reappearance of pancreatic swelling or narrowing of the main pancreatic duct (MPD) and resumption or dose increase of corticosteroids for extrapancreatic lesions, 12 reappearance of symptoms with pancreatic and/or extrapancreatic abnormalities in imaging studies, 13, 22 and pancreatic swelling or narrowing of the MPD and new or worsening extrapancreatic lesions. 23 To obtain objective evidence, we defined relapse as the reappearance or exacerbation of pancreatic or extrapancreatic organ lesions recognized by imaging at diagnosis or during MT that had initially improved by remission therapy.
We evaluated medical records retrospectively and recorded clinical features at diagnosis, serum activity markers, and imaging findings at diagnosis and at 3 years of MT, as described hereinafter.
Clinical Features
Clinical features at diagnosis included age, sex, body mass index, history of alcohol intake, smoking, or allergy, past treatment of diabetes mellitus, jaundice at diagnosis, follow-up period and duration of corticosteroid therapy, reason for corticosteroid induction, and corticosteroid dose at 3 years of MT.
Laboratory Findings
Laboratory findings included such serum activity markers as serum IgG, IgG4, soluble interleukin 2 receptor, β 2 -microglobulin, C3, C4, and immune complex (IC) monoclonal rheumatoid factor, at diagnosis and at 3 years of MT. The reduction rates of IgG and IgG4 values at 3 years of MT relative to those at diagnosis were also evaluated.
Imaging Findings
We evaluated imaging findings of pancreatic lesions (swelling pattern at the head, body, and tail) and other organ involvements (OOIs), as well as the number of OOIs at diagnosis. In this study, OOIs were defined as lacrimal/salivary lesions, lung lesions, pulmonary hilar or mediastinal lymph node lesions, bile duct lesions, kidney lesions, and retroperitoneal fibrosis showing swelling or wall thickening that responded well to corticosteroid therapy. Extrapancreatic bile duct lesions were evaluated based on endoscopic retrograde cholangiography. Lung lesions and hilar lesions included mild lesions responding well to corticosteroid therapy. Lung lesions were evaluated for mass, nodularity, ground-glass opacity, thickening of bronchovascular bundles, and interlobular septae by chest computed tomography (CT) images. We also measured the anteroposterior diameter of affected pancreatic parenchyma at diagnosis and at 3 years of MT for calculations of reduction rate. The pancreatic head was defined as the right-side portion from the left-side edge of the superior mesenteric and portal veins. The pancreatic body and tail were separated by a line equally dividing the remaining portion. The anteroposterior diameter of pancreatic parenchyma was measured as the maximal diameter of each head, body, and tail parts of cross-sectional enhanced CT images. Pancreatic head diameter was measured by a line through the center of the superior mesenteric vein and vertical to the spinous processes of the vertebrae. The diameters of the pancreatic body and tail were measured by a line vertical to the MPD. We also assessed for pancreatic stone formation and calcification after AIP diagnosis.
Relapse
We evaluated the number and organs of relapses occurring during the 3 years after corticosteroid introduction and searched for relationships with those after 3 years of MT.
Statistical Analysis
In univariate analysis, the Mann-Whitney U test was used for continuous variables, and the χ 2 and Fisher's exact tests were adopted for qualitative variables. Receiver operating characteristic (ROC) curves were calculated to establish cutoff values for the continuous variables exhibiting significant differences. The Cox proportional hazards model was used for multivariate analysis. The Kaplan-Meier survival method and log-rank test were used for determining cumulative relapse rate. P values of less than 0.05 were considered statistically significant. Analyses were performed using Statflex software, version 6.0 (Artech Co, Ltd, Osaka, Japan).
Ethics
The present study was approved by the ethics committee of Shinshu University School of Medicine (approval number: 3596).
RESULTS
The risk factors associated with relapse after 3 years of MT were assessed as described hereinafter.
Parameters at Diagnosis

Clinical Features
Relapse patients had significantly less frequent jaundice than nonrelapse patients at diagnosis (P = 0.005), with no other significant differences between the groups (Table 1) .
Laboratory Findings
The relapse group had significantly higher serum IgG and significantly lower serum C3 values than did the nonrelapse group (P = 0.005 and P = 0.022; Table 1 ).
Imaging Findings
There were no significant differences in the locations of pancreatic swelling or bile duct lesions between the groups. The relapse group had significantly more frequent lacrimal/salivary gland lesions (P = 0.003), lung lesions (P = 0.042), kidney lesions (P = 0.020), and retroperitoneal fibrosis (P = 0.011) than did the nonrelapse group. Patients with at least 4 OOI lesions at diagnosis were also significantly more likely to relapse than those without (P = 0.002; Table 2 ).
Relationships With Corticosteroid Therapy
Observation and Corticosteroid Administration Periods
There were no significant differences in observation period, corticosteroid administration period, or daily corticosteroid dose at 3 years of MT between the relapse and the nonrelapse groups after 3 years of MT. There were no statistical differences in relapse rate after 3 years of MT for corticosteroid doses of at most 2.5 mg/day versus greater than 2.5 mg/day or at most 5 mg/day versus greater than 5 mg/day (data not shown). The indication for corticosteroid therapy in the relapse group favored extrapancreatic lesions apart from bile duct lesions more frequently than in the nonrelapse group (P = 0.038; Table 3 ).
Relapse During the 3 Years After Corticosteroid Introduction
There were no significant differences in the frequency or distribution of relapse during the 3 years after corticosteroid introduction between the groups (data not shown).
Relapse Organs After 3 Years of MT
The pancreas was the most prevalent relapse organ after 3 years of MT (Table 4) .
Laboratory Findings at 3 Years of MT
The relapse group had significantly higher serum IgG and IgG4 values at 3 years of MT than did the nonrelapse group (P = 0.018 and P = 0.020; Table 5 ). At 3 years of MT, normalization of IgG4 (<135 mg/dL) was found in 1 (8.3%) of 12 patients, and normalization of IgG (<1700 mg/dL) was seen in 8 (61.5%) of 13 patients in the relapse group. IgG4 and IgG normalization was detected in 5 (27.8%) of 18 patients and 13 (76.4%) of 17 patients, respectively, in the nonrelapse group. There were no significant differences in the reduction rate of IgG or IgG4 values between the time of 3 years of MT and at diagnosis between the groups. In ROC curve analysis, serum IgG of 1400 mg/dL and IgG4 of 330 mg/dL at 3 years of MT were the optimal cutoff values to predict relapse after 3 years of MT, with a sensitivity of 84.6%, a specificity of 70.8%, and an area under the ROC curve (AUC) of 0.739 for a serum IgG cutoff of 1400 mg/dL and a sensitivity of 75.8%, a specificity of 71.4%, and an AUC of 0.746 for a serum IgG4 cutoff value of 330 mg/dL.
Relationship With Pancreatic Imaging Findings
Anteroposterior Diameter of Pancreatic Parenchyma
There was no significant difference in the anteroposterior diameter of pancreatic parenchyma at diagnosis between the groups. At 3 years of MT, the relapse group had a significantly thicker pancreatic head and tail than did the nonrelapse group (P = 0.045 and P = 0.024; Table 6 ). The optimal cutoff values predicting relapse after 3 years of MT were 15 mm for pancreatic head and 20 mm for pancreatic tail at 3 years of MT, with sensitivities of 85.7% and 62.5%, specificities of 77.8% and 83.4%, and AUCs of 0.778 and 0.781.
Reduction Rate of Anteroposterior Diameter of Pancreatic Parenchyma
The relapse group had a significantly lower reduction rate of anteroposterior diameter of the pancreatic head at 3 years of MT compared with diagnosis than did the nonrelapse group (P = 0.025; data not shown). A reduction rate of 45% provided the optimal cutoff value to predict relapse after 3 years of MT, with a sensitivity of 83.3%, a specificity of 83.3%, and an AUC of 0.810.
Pancreatic Stone Formation and Calcification
At AIP diagnosis, there were 3 patients each with pancreatic calcification in the relapse and nonrelapse groups. After AIP diagnosis, 1 patient with pancreatic stone formation and 1 patient with calcification were found in the relapse group, whereas in the nonrelapse group, 2 patients with calcification were detected. There were no significant differences in pancreatic stone or calcification rates (data not shown).
Multivariate Analysis
Predictive Factors of Relapse After 3 Years of Oral Corticosteroid MT
Cox proportional hazards regression analysis was conducted to confirm the optimal parameters for predicting relapse after 3 years of MT. Candidate variables were selected from the clinical and imaging findings at diagnosis and serological variables at 3 years of MT showing significant differences in univariate analysis. Predictive variables were selected using the bidirectional elimination method. According to multivariate analysis, OOI number of 4 or more at diagnosis (hazard ratio (Table 7) .
Analysis of Relapse Prediction Factors After 3 Years of MT
We divided the cohort into groups with and without individual relapse prediction factors and examined the cumulative relapse rate after 3 years of MT by using the Kaplan-Meier testing and the log-rank test. The groups with OOI number of 4 or more at diagnosis or serum IgG of 1400 mg/dL or greater at 3 years of MT showed significantly higher cumulative relapse rates than did the counterpart groups (P = 0.001 and P < 0.001; Figs. 1A, B) . One (7.1%) of the 14 patients without either predictive factor showed relapse, 3 (25%) of 12 patients with 1 predictive factor exhibited relapse, and 9 (81.8%) of 11 patients with 2 predictive factors showed relapse. Based on these results, the group with both predictive factors had a significantly higher cumulative relapse rate than did the group with none or 1 predictive factor (P < 0.001; Fig. 1C ).
DISCUSSION
The present study revealed a close association between specific risk factors and relapse after 3 years of oral corticosteroid MT. These parameters may provide useful information in deciding whether to continue long-term treatment and in constructing therapeutic strategies for extended periods.
Predictive Factors for Relapse After 3 Years of Oral Corticosteroid Maintenance Therapy
Clinical Features
Univariate analysis of clinical features at diagnosis showed less frequent jaundice in the relapse group, which was in contrast to previous reports indicating jaundice at diagnosis to be a risk factor for relapse. [24] [25] [26] One reason for this unexpected result may be that the indication for corticosteroid therapy in the relapse group favored extrapancreatic lesions other than bile duct lesions compared with the nonrelapse group, resulting in a lower incidence of jaundice.
Laboratory Findings
The relapse group had higher serum IgG at diagnosis and higher serum IgG and IgG4 at 3 years of MT than did the nonrelapse group. Previous studies have reported elevated serum IgG4 at diagnosis, 24, 27, 28 persistently high IgG4 after corticosteroid induction, 29 and a low reduction rate of IgG4 after corticosteroid induction 23 as predictive factors for relapse, suggesting that cases under insufficient disease activity control by corticosteroids could easily relapse during treatment. Hirano et al 30 focused on changes in serum IgG and IgG4 before and after corticosteroid therapy and found that 46 (96%) of 48 AIP patients exhibited normal serum IgG (ie, <1800 mg/dL) after remission induction therapy. The ROC curve analysis revealed the optimal cutoff value in distinguishing between aggravation and remission phases to be 1600 mg/dL (77% sensitivity, 94% specificity, and 85% accuracy). In the same way, 13 of 42 AIP patients showed normal serum IgG4 (ie, <135 mg/dL) after remission induction therapy, with an optimal cutoff value for this differentiation of 244 mg/dL (81% sensitivity, 67% specificity, and 74% accuracy). These proposed cutoff values are in agreement with the IgG and IgG4 cutoff values at 3 years of MT in our cohort. Based on the previously mentioned studies, serum IgG and IgG4 values less than 1400 and 330 mg/dL, respectively, have been approved as suitable benchmarks for disease control under MT. However, IgG, not IgG4, seems to be a more reliable marker for relapse in this study based on a multivariate model. Shiokawa et al 31 found that in a neonatal mouse model, pancreatic injury was induced by injecting human AIP IgG1 or IgG4, with more destructive changes induced by the former. The potent pathogenic activity of IgG1 was significantly inhibited by simultaneous injection of IgG4. These results suggested that pathogenic autoantibodies of AIP are included in the IgG1 subclass, a major part of IgG, and not in the IgG4 subclass, and indicated that IgG was a more reliable predictor of relapse than IgG4. The relapse group also had significantly lower serum C3 at diagnosis than did the nonrelapse group. Muraki et al 32 reported that active-phase AIP patients exhibited high serum IC values, and those with high serum IC determined by C1q assays had a tendency for low serum C3, significantly low serum C4, and high serum IgG1. Accordingly, complement levels before corticosteroid therapy might be reflected in disease activity during treatment.
Imaging Findings
The relapse group was significantly more frequently complicated with lacrimal/salivary gland lesions, lung lesions, kidney lesions, retroperitoneal fibrosis, and at least 4 OOIs at diagnosis compared with the nonrelapse group. Extrapancreatic lesions of the lacrimal/salivary glands 33, 34 and bile duct 6, 11, 26, 28 are reported risk factors for relapse. Taken together, AIP cases with multiorgan lesions at diagnosis may possess high disease activity and be more predisposed to relapse after 3 years of MT. A shortcoming of this study was that imaging analysis of lacrimal/salivary gland and other head lesions was not evaluated in all nonrelapse group patients, which may have accounted for no significant associations in multivariate analysis. Another shortcoming is that the number of OOIs may have varied according to the observer or individual institution.
Pancreatic imaging analysis showed that the relapse group had significantly thicker pancreatic head and tail regions and a lower reduction rate of the pancreatic head region at 3 years of MT than did the nonrelapse group. Ohno et al 22 reported that AIP patients with a large pancreatic volume or less pancreatic volume reduction after treatment were more predisposed to relapse, indicating that posttreatment pancreatic thickness might reflect disease activity in the remission phase of AIP. We believe that anteroposterior diameter measurement of pancreatic parenchyma is simpler than volume measurement and represents a useful way to predict relapse in daily clinical care. However, an insufficient number of cases were analyzed for lesions among pancreatic sections, which might have been a reason why multivariate analysis did not show these factors as predictive of relapse. We observed no significant differences in the location or extent of pancreatic lesions between the 2 groups. Some studies reported diffuse pancreatic swelling 13, 35 and diffuse pancreatic duct lesions 33 as risk factors of relapse, whereas another found no significant difference in relapse rate between diffuse and localized pancreatic swelling. 6 The results of the present investigation support the latter notion; there were no significant differences in the incidence of pancreatic calcification between the relapse and nonrelapse groups, although our previous study had indicated that pancreatic calcification was significantly associated with relapse. 36 This discrepancy may have been due to insufficient patient number and differences in the definition of relapse.
Relationships With Corticosteroid Therapy
There were no significant differences in daily corticosteroid dose at 3 years of MT between the relapse group and the nonrelapse group, possibly because the corticosteroid dose might have been insufficient in the relapse group.
Strategy for Long-term AIP Treatment Based on Proposed Predictive Factors of Relapse
Using multivariate analysis, we identified number of OOI of 4 or more at diagnosis and IgG of 1400 mg/dL or greater at 3 years of MT as predictive factors of relapse after 3 years of MT in AIP. Kubota et al 13 described the relapse rate of AIP patients under MT in a large-scale retrospective cohort study of 510 cases to be 10% within a year, 25.8% within 3 years, 35.1% within 5 years, and plateauing at 43% at 7 years; relapse rate increased over 7 years of MT, indicating that persistent therapy was needed even after 3 years. Autoimmune pancreatitis patients with both relapse prediction factors may have a considerable risk of relapse after 3 years of MT and are therefore advised to continue treatment to prevent recurrence and undergo careful follow-up for early detection and management of subclinical relapse. Shimizu et al 18 reported greater than 8694 mg of cumulative corticosteroid administration to be a risk factor for severe adverse drug effects. In accordance with these results, Kubota et al 13 concluded that MT of 5 mg/d for 3 years would be comparatively safe, because of that, total corticosteroid dose would be 4625 mg of cumulative corticosteroids at 2 years and 6425 mg at 3 years. Patients with none or 1 predictive factor are regarded to be at low risk of relapse after 3 years of MTowing to low disease activity and may be candidates for corticosteroid discontinuation to avoid adverse effects. Accordingly, patients with IgG of less than 1400 mg/dL at 3 years of MT and/or less than 4 OOIs at diagnosis may be candidates for cessation of corticosteroids, but the unpredictability of an IgG increase after stopping MT remains a risk.
CONCLUSIONS
In the present study, we revealed 2 predictive factors for AIP relapse after 3 years of corticosteroid MT: OOI number of at least 4 at diagnosis and IgG of at least 1400 mg/dL at 3 years of MT. Relapse was associated with the number of these predictive factors, which will provide useful information in deciding corticosteroid therapy regimens at 3 years of MT to minimize AIP relapse and adverse drug effects.
